Loading
Life sciences · Journal article
Bladder · September 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The SWOG S1011 randomized controlled trial provided level-one evidence demonstrating no significant advantage of extended lymph node dissection (ELND) over standard lymph node dissection (SLND) in terms of recurrence-free and overall survival for patients with muscle-invasive bladder cancer (MIBC) undergoing radical cystectomy (RC). However, the generalizability of these findings to real-world North American practice remains unclear. To assess the external validity of this trial, we used data from the National Cancer Database (NCDB) to simulate the original trial inclusion criteria, identifying patients with clinical T2–4a, N0–2 bladder cancer who underwent RC with LND between 2010 and 2022. Sociodemographic and clinical characteristics of the NCDB cohort were compared with those reported in the SWOG S1011 trial. Although the original trial excluded robot-assisted RC, both open and robotic approaches were included in this analysis and evaluated separately. Overall, 26,183 patients underwent RC, of whom 16,814 (64.3%) received open RC and 9,369 (35.7%) robot-assisted RC. No clinically meaningful differences were observed between cohorts in terms of age, sex, or self-reported race. In contrast, patients enrolled in the trial were more likely to present with cT3–4a disease and to receive neoadjuvant systemic therapy, resulting in a lower proportion of pT≥2 N0 tumors compared with patients treated in routine practice. Moreover, the median number of lymph nodes removed in both the SLND and ELND trial arms was substantially higher than that observed in the NCDB open and robotic RC cohorts. These findings suggest that while the SWOG S1011 trial provides robust evidence against an oncological benefit of ELND over SLND in MIBC, its external validity is only partially supported, and differences from contemporary real-world practice may limit the generalizability of its conclusions.